Literature DB >> 26611584

Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids.

Michael J Castle1,2, Heikki T Turunen3, Luk H Vandenberghe3, John H Wolfe4,5,6.   

Abstract

More than one hundred naturally occurring variants of adeno-associated virus (AAV) have been identified, and this library has been further expanded by an array of techniques for modification of the viral capsid. AAV capsid variants possess unique antigenic profiles and demonstrate distinct cellular tropisms driven by differences in receptor binding. AAV capsids can be chemically modified to alter tropism, can be produced as hybrid vectors that combine the properties of multiple serotypes, and can carry peptide insertions that introduce novel receptor-binding activity. Furthermore, directed evolution of shuffled genome libraries can identify engineered variants with unique properties, and rational modification of the viral capsid can alter tropism, reduce blockage by neutralizing antibodies, or enhance transduction efficiency. This large number of AAV variants and engineered capsids provides a varied toolkit for gene delivery to the CNS and retina, with specialized vectors available for many applications, but selecting a capsid variant from the array of available vectors can be difficult. This chapter describes the unique properties of a range of AAV variants and engineered capsids, and provides a guide for selecting the appropriate vector for specific applications in the CNS and retina.

Entities:  

Keywords:  AAV; Adeno-associated virus; Capsid; Gene delivery; Gene therapy; Serotype; Vector; Virus

Mesh:

Year:  2016        PMID: 26611584      PMCID: PMC4993104          DOI: 10.1007/978-1-4939-3271-9_10

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  131 in total

1.  Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain.

Authors:  Cassia N Cearley; John H Wolfe
Journal:  Mol Ther       Date:  2006-01-18       Impact factor: 11.454

2.  High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors.

Authors:  Hilda Petrs-Silva; Astra Dinculescu; Qiuhong Li; Seok-Hong Min; Vince Chiodo; Ji-Jing Pang; Li Zhong; Sergei Zolotukhin; Arun Srivastava; Alfred S Lewin; William W Hauswirth
Journal:  Mol Ther       Date:  2008-12-16       Impact factor: 11.454

3.  microRNA122-regulated transgene expression increases specificity of cardiac gene transfer upon intravenous delivery of AAV9 vectors.

Authors:  A Geisler; A Jungmann; J Kurreck; W Poller; H A Katus; R Vetter; H Fechner; O J Müller
Journal:  Gene Ther       Date:  2010-11-04       Impact factor: 5.250

4.  Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector.

Authors:  Dolan Sondhi; Neil R Hackett; Daniel A Peterson; Jamie Stratton; Michael Baad; Kelly M Travis; James M Wilson; Ronald G Crystal
Journal:  Mol Ther       Date:  2006-12-19       Impact factor: 11.454

Review 5.  Receptors and tropisms of envelope viruses.

Authors:  Kouki Morizono; Irvin S Y Chen
Journal:  Curr Opin Virol       Date:  2011-07       Impact factor: 7.090

6.  Adeno-associated virus vector-mediated transduction in the cat brain.

Authors:  Charles H Vite; Marco A Passini; Mark E Haskins; John H Wolfe
Journal:  Gene Ther       Date:  2003-10       Impact factor: 5.250

7.  Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells.

Authors:  P L Hermonat; N Muzyczka
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

8.  In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous.

Authors:  Deniz Dalkara; Leah C Byrne; Ryan R Klimczak; Meike Visel; Lu Yin; William H Merigan; John G Flannery; David V Schaffer
Journal:  Sci Transl Med       Date:  2013-06-12       Impact factor: 17.956

9.  Glial promoter selectivity following AAV-delivery to the immature brain.

Authors:  Georg von Jonquieres; Nadine Mersmann; Claudia Bettina Klugmann; Anne Editha Harasta; Beat Lutz; Orla Teahan; Gary David Housley; Dominik Fröhlich; Eva-Maria Krämer-Albers; Matthias Klugmann
Journal:  PLoS One       Date:  2013-06-14       Impact factor: 3.240

10.  Corticospinal tract transduction: a comparison of seven adeno-associated viral vector serotypes and a non-integrating lentiviral vector.

Authors:  T H Hutson; J Verhaagen; R J Yáñez-Muñoz; L D F Moon
Journal:  Gene Ther       Date:  2011-05-12       Impact factor: 5.250

View more
  49 in total

Review 1.  Viral vector-based tools advance knowledge of basal ganglia anatomy and physiology.

Authors:  Rachel J Sizemore; Sonja Seeger-Armbruster; Stephanie M Hughes; Louise C Parr-Brownlie
Journal:  J Neurophysiol       Date:  2016-02-17       Impact factor: 2.714

Review 2.  Gene therapy and genome surgery in the retina.

Authors:  James E DiCarlo; Vinit B Mahajan; Stephen H Tsang
Journal:  J Clin Invest       Date:  2018-06-01       Impact factor: 14.808

3.  AAV-PHP.B Administration Results in a Differential Pattern of CNS Biodistribution in Non-human Primates Compared with Mice.

Authors:  William A Liguore; Jacqueline S Domire; Dana Button; Yun Wang; Brett D Dufour; Sathya Srinivasan; Jodi L McBride
Journal:  Mol Ther       Date:  2019-08-05       Impact factor: 11.454

Review 4.  Viral vectors for therapy of neurologic diseases.

Authors:  Sourav R Choudhury; Eloise Hudry; Casey A Maguire; Miguel Sena-Esteves; Xandra O Breakefield; Paola Grandi
Journal:  Neuropharmacology       Date:  2016-02-21       Impact factor: 5.250

5.  Global Connectivity and Function of Descending Spinal Input Revealed by 3D Microscopy and Retrograde Transduction.

Authors:  Zimei Wang; Brian Maunze; Yunfang Wang; Pantelis Tsoulfas; Murray G Blackmore
Journal:  J Neurosci       Date:  2018-10-19       Impact factor: 6.167

6.  An Engineered Galactosylceramidase Construct Improves AAV Gene Therapy for Krabbe Disease in Twitcher Mice.

Authors:  Xiufang Pan; Scott A Sands; Yongping Yue; Keqing Zhang; Steven M LeVine; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2019-07-18       Impact factor: 5.695

Review 7.  Emerging Gene Therapies for Genetic Hearing Loss.

Authors:  Hena Ahmed; Olga Shubina-Oleinik; Jeffrey R Holt
Journal:  J Assoc Res Otolaryngol       Date:  2017-08-16

8.  Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.

Authors:  Junjiang Sun; Baolai Hua; Xiaojing Chen; Richard J Samulski; Chengwen Li
Journal:  Hum Gene Ther       Date:  2017-05-05       Impact factor: 5.695

Review 9.  Virus-Derived Peptides for Clinical Applications.

Authors:  Mingying Yang; Kegan Sunderland; Chuanbin Mao
Journal:  Chem Rev       Date:  2017-07-19       Impact factor: 60.622

10.  Global CNS correction in a large brain model of human alpha-mannosidosis by intravascular gene therapy.

Authors:  Sea Young Yoon; Jacqueline E Hunter; Sanjeev Chawla; Dana L Clarke; Caitlyn Molony; Patricia A O'Donnell; Jessica H Bagel; Manoj Kumar; Harish Poptani; Charles H Vite; John H Wolfe
Journal:  Brain       Date:  2020-07-01       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.